Diverse women standing together in solidarity Medical research environment Never ever give up - children encouragement drawings Patient in hospital bed
85%

ONE WORLD | ONE FIGHT

Global Platform for Breast Cancer and other Female Cancers

Fund the science that saves lives. Not galas. Not ribbons. Research.

85% of every donation funds research →
Registered
501(c)(3) New York
Allocation
85% to research
Reviewed
SRAC peer review
Audited
SHRK CPAs annually

Cancer doesn’t fly
business class.
Neither do we.

Most cancer charities can’t tell you where your money goes. We name the scientist, the institution, the TRL level, and the cancer type. Every grant. Every dollar.

Get involved

How you can help.

Every action moves the science forward. Choose the path that fits you.

Fund Research

Your donation goes directly to TRL 3–5 research at verified institutions. 85 cents of every dollar. Tracked to the grant.

Corporate Partnership

Align your brand with verifiable science. Named researcher, named institution, named TRL level. Not pink-washing — proof.

Spread the Word

Share our mission. Follow our research updates. Help us reach the people who believe science should come first.

Financial architecture

Built to be lean.
Not aspirational.

85 cents of every dollar funds research. 15 cents runs the entire operation. This isn’t a target. It’s a constraint encoded in our bylaws.

85|15
Research — 85%Operations — 15% max
Radical transparency

We publish everything.

Every grant. Every dollar. Every result. Our open books are coming — full financial transparency so you can verify exactly where your money went. No charities hiding behind “overhead ratios.” Just the numbers.

Grant amounts
Researcher names
Institution details
Annual audits
Scope

Breast Cancer and other Female Cancers

We fund research across all female gender-related cancers: gynaecological cancers that only affect women, plus breast cancer.

Tile colour reflects research attention and funding. Lightest pinks mark the cancers most commonly discussed — deeper pinks highlight the rare and under-researched ones that receive far less support.

Breast

Most common

Cervical

Preventable

Ovarian

Silent killer

Fallopian tube

Often grouped with ovarian

Womb (uterine)

Rising incidence

Vaginal

Very rare

Vulval

Under-researched

Most common Rare

“We name the scientist, the institution, and the exact TRL level your donation funded.”

Technology readiness levels

We fund the exact gap where science dies.

Most funding goes to basic research (TRL 1–2) or late-stage trials (TRL 6–9). The critical middle is chronically underfunded. Pharma won’t touch it. Governments overlook it. We exist to fill that gap.

1
2
3
4
5
6
7
8
9
Basic research
The valley of death
Clinical & market

Why this gap kills breakthroughs

TRL 3–5 is where discoveries have proven their concept but can’t attract pharmaceutical investment. A BRCA marker identified at Queen’s Belfast. A detection method validated at MD Anderson. Without bridge funding, this science simply dies. We make sure it doesn’t.

TRL 3

Proof of concept

The science works in the lab. Needs validation in relevant biological systems.

TRL 4

Validated in models

Results confirmed in disease models. The mechanism is real. Capital needed.

TRL 5

Pre-clinical evidence

Strong data. The tipping point where pharma pays attention — if science gets here.

“The gap between discovery and cure isn’t scientific — it’s financial.

Institutional partners

Named researchers.
Verified institutions.
Follow the science.

Named scientists at verified institutions, doing published work you can look up yourself.

World #1 cancer centre
MD Anderson Cancer Center
Houston, Texas
Comprehensive cancer research across all female gender-related cancers
Patrick G Johnston Centre
Queen’s University Belfast
Belfast, Northern Ireland
BRCA mutation detection & genetic risk profiling
Prof. Nick Orr — Cancer Genetics
Prof. Kienan Savage — Molecular Oncology
HIC ↔ LMIC Bridge
Tata Medical Centre
Kolkata, India
Bridging high-income research into LMIC clinical practice
Dr. Shrikant Atreya — Palliative Care & Clinical Integration
Scientific Review Advisory Committee
Independent peer review

Every grant is evaluated by independent scientists before a single dollar moves. Rigour only.

Prof. Nick Orr Queen’s Belfast
Prof. Kienan Savage Queen’s Belfast
Prof. Karen Flegg ANU Canberra
Dr. Shrikant Atreya Tata Medical
Prof. David Weller Edinburgh
Dr. Sarah Friend myFriendMD
Prof. A. Akhator Delta State
Accountability

Follow the money. Every step.

01

You donate

Tax-deductible. Secure via Stripe or PayPal. Tracked from arrival.

02

SRAC reviews

Independent scientists evaluate for rigour and TRL 3–5 alignment.

03

Grants awarded

85% flows to approved research. Named institution. Named researcher.

04

Results published

Open updates. Annual reports. Full financial transparency.

Impact

The faces behind the science.

Real researchers. Real breakthroughs. Stories from the labs your donations fund.

Coming soon

A BRCA breakthrough in Belfast

How a TRL 3 discovery at Queen’s University Belfast moved closer to clinical validation — funded by donors like you.

Coming soon

Ovarian cancer detection at MD Anderson

Early-stage detection research that could change survival rates — currently at TRL 4 and advancing.

Coming soon

Cervical cancer prevention in Mumbai

Tata Medical Centre researchers developing affordable screening methods for underserved populations.

ONE WORLD | ONE FIGHT

Monthly donors receive quarterly briefings — named researchers, real results, actual science.

Donate now
Global presence

Global PinkRibbon Map

One movement, 96 countries. Every highlighted nation stands with PinkRibbon International.

PinkRibbon Countries Support Referral Other Countries